Gastric Cancer in Older Adults: Balancing Treatment and Quality of Life
"A real-world look at second-line treatment efficacy and toxicity in older versus younger patients reveals key insights for managing advanced gastric cancer."
Gastric cancer, a significant global health concern, disproportionately affects older adults. While its incidence rises with age, older patients are often underrepresented in clinical trials, making it challenging to determine the most effective and safe treatment strategies for this population.
A recent multi-center study published in the Journal of Geriatric Oncology sheds light on this critical issue. Researchers compared the experiences of older (70+) and younger patients with advanced gastric cancer who received at least two lines of chemotherapy. The goal was to identify differences in treatment efficacy, toxicity, and overall survival to inform more tailored treatment approaches for older adults.
This article delves into the study's findings, highlighting key differences in tumor characteristics, treatment choices, and outcomes. It offers valuable insights for healthcare professionals and individuals seeking a better understanding of how age influences the management of advanced gastric cancer and how to optimize treatment strategies while prioritizing quality of life.
The Growing Burden in Older Adults
About 6 in 10 people diagnosed with stomach cancer each year are 65 or older, according to the American Cancer Society. A 2026 analysis reports that stomach cancer mortality rates declined substantially among adults aged 65 and older, but absolute deaths declined less because population growth and ageing offset epidemiological gains. The burden is increasingly concentrated at the oldest ages, making both age-standardised rates and absolute deaths important measures of impact.
Individualized Treatment Decisions
Treatment for older adults generally requires balancing cancer control against functional status, other health conditions, treatment tolerance, and personal goals. Evidence may be less definitive for this population because older adults are not always represented equally in clinical research. Consequently, treatment decisions are best understood as individualized rather than determined by chronological age alone.
An Evolving Treatment Landscape
The management of gastric cancer has developed through successive improvements in diagnosis, surgery, systemic therapy, and supportive care. For older adults, the historical shift has increasingly emphasized whether treatment preserves meaningful function and quality of life, not only whether it extends survival. The evidence base remains an evolving foundation for more tailored care.
Key Findings: How Age Impacts Gastric Cancer Treatment
The study, led by Valentina Fanotto and colleagues, analyzed data from 868 patients with advanced gastric cancer across multiple Italian oncology centers. Of these, 276 patients (31.8%) were 70 years or older at the start of second-line chemotherapy. The researchers meticulously compared various factors between the older and younger groups, including:
- Tumor characteristics (histology, differentiation, stage)
- Treatment regimens (single-agent vs. combination chemotherapy)
- Survival outcomes (progression-free survival (PFS) and overall survival (OS))
- Treatment-related toxicities and adverse events
Current Evidence for Older Patients
Recent reviews continue to examine treatment for older adults across perioperative, adjuvant, and palliative settings. They also highlight the need to account for physiological heterogeneity, reduced treatment tolerance, and differing patient goals. The available evidence therefore supports careful assessment and individualized treatment planning rather than a single age-based strategy.
Limits of the Evidence
A major limitation in this field is that evidence for older adults is often limited or drawn from subgroup analyses of randomized trials. Such data may not fully represent the physiological diversity, comorbidities, or treatment priorities found in routine older-patient care. Apparent treatment benefits must therefore be interpreted alongside tolerability and the goals that matter to each patient.
Comparing Strategies for Older Adults
Reviews describe older adults as a heterogeneous group in whom reduced treatment tolerance and different goals can influence perioperative, adjuvant, and palliative decisions. A 2025 review reports that gastric cancer primarily affects older adults, with a median diagnosis age of approximately 68 years and more than half of cases in East Asia occurring among people aged 65 or older. However, the 2017 review notes that much of the evidence for patients over 65 comes from subgroup analyses of randomized trials, limiting direct comparisons between strategies.
Personalized Care: The Future of Gastric Cancer Treatment in Older Adults
This study reinforces the importance of individualized treatment plans that consider not just age but also overall health status, tumor characteristics, and patient preferences. While further research is needed, this study provides valuable insights for optimizing treatment strategies and improving the quality of life for older adults facing advanced gastric cancer. By challenging preconceived notions about age and treatment intensity, this research paves the way for more personalized and effective care for all patients.
Interpreting Real-World Outcomes
A 2026 study examines disparities in treatment use and survival among older patients with advanced gastric cancer in the context of rapidly ageing populations. Separately, a single-center retrospective analysis reported treatment outcomes for 61 patients aged 80 or older with non-metastatic gastric or cardio-esophageal junction cancer. Together, these studies illustrate why conclusions about older adults should consider both real-world treatment patterns and outcomes in carefully defined patient groups.
Toward More Personalized Care
Future research is likely to focus on treatment selection that better reflects the biological and functional diversity of older adults. A comprehensive review describes gastric cancer as a major unmet clinical problem, with more than 1 million new cases worldwide in 2018. A network meta-analysis specifically among senior gastric cancer patients compared survival outcomes across treatment regimens, offering evidence intended to inform future clinical practice and research design.
Ageing and Regional Burden
Gastric cancer is described as the fifth most common cancer worldwide and the fifth leading cause of cancer-related death. Its incidence and mortality are notably high in East Asia, where more than half of cases occur in people aged 65 or older and the median age at diagnosis is approximately 68 years. These patterns make ageing populations and regional differences important considerations in treatment planning and health-system responses.
Quality of Life in Treatment Decisions
For an older person with gastric cancer, treatment decisions involve more than tumor control alone. Functional status, treatment tolerance, independence, and the outcomes the patient values can all shape the balance between extending life and preserving quality of life. Care that explicitly incorporates these priorities may be better aligned with the realities of ageing and serious illness.